Targeting FOXO3 may represent a novel strategy for the development of therapies against Alzheimer’s disease (AD) and cognitive impairment, as it plays a crucial role in promoting neuronal cell death by upregulating BIM during glutamate-associated excitotoxicity and amyloid-β peptide (Aβ) toxicity, both hallmarks of AD [49–55]. This evidence concerns the gene BCL2L11 and Alzheimer disease.